Consensus IDEXX Laboratories, Inc.

Stocks

IDXX

US45168D1046

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 01:30:00 02/10/2026 am IST			5-day change	1st Jan Change
517.75 ^USD	-0.85%		-0.82%	-23.47%

01/10	IDEXX Laboratories Acquires Veterinary AI Platform CoVetAI	MT
17/09	Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Amid Economic Data, Fed Rate Hike	MT

Evolution of the Average Target: IDEXX Laboratories, Inc.

Evolution of the Target Price: IDEXX Laboratories, Inc.

Changes in Analyst Recommendations: IDEXX Laboratories, Inc.

d9.gfOzoL5CV6FXwIOXdRJXWKsWb2sJjfy8S4maX95Ar5k.0Yfh1sghJ9UW8OvwQiojKp1UJ14k_M_jLcCiLbgk3N3ygd3Giwc88Q-u9A~2fde2d5daab73ab6fedaeb1e990663b3

Analysts' recommendations: IDEXX Laboratories, Inc.

11/08	Barclays Adjusts Price Target on IDEXX Laboratories to $710 From $800, Keeps Overweight Rating	MT
05/08	Jefferies Adjusts Price Target on IDEXX Laboratories to $795 From $792	MT
05/08	Citigroup Adjusts Price Target on IDEXX Laboratories to $670 From $650	MT
05/08	UBS Adjusts Price Target on IDEXX Laboratories to $670 From $620, Maintains Neutral Rating	MT
27/07	Elanco Seems Best-Positioned Into Q2 Print Among Animal Health Stocks, UBS Says	MT
27/07	UBS Cuts IDEXX Laboratories Price Target to $620 From $640, Maintains Neutral Rating	MT
13/07	Leerink Partners Adjusts IDEXX Laboratories Price Target to $715 From $725, Maintains Outperform Rating	MT
06/05	Rothschild & Co Redburn Adjusts Price Target on IDEXX Laboratories to $665 From $655	MT
06/05	Jefferies Adjusts Price Target on IDEXX Laboratories to $792 From $785	MT
28/04	UBS Adjusts Price Target on IDEXX Laboratories to $640 From $730, Maintains Neutral Rating	MT
27/04	Jefferies Adjusts Price Target on IDEXX Laboratories to $785 From $820, Maintains Buy Rating	MT
15/04	Citigroup Initiates IDEXX Laboratories at Neutral With $650 Price Target	MT
14/04	Leerink Partners Adjusts IDEXX Laboratories PT to $725 From $760, Maintains Outperform Rating	MT
31/03	Stifel Nicolaus Adjusts IDEXX Laboratories PT to $675 From $775, Maintains Buy Rating	MT
09/02	Piper Sandler Adjusts Price Target on IDEXX Laboratories to $750 From $775, Maintains Neutral Rating	MT
05/02	Barclays Adjusts Price Target on IDEXX Laboratories to $800 From $850, Maintains Overweight Rating	MT
05/02	Barclays Lowers Price Target on IDEXX Laboratories to $800 From $850	MT
03/02	Jefferies Adjusts Price Target on IDEXX Laboratories to $820 From $830	MT
03/02	UBS Adjusts IDEXX Laboratories PT to $730 From $750	MT
03/02	Leerink Partners Adjusts Price Target on IDEXX Laboratories to $760 From $785	MT
03/02	BTIG Adjusts Price Target on IDEXX Laboratories to $800 From $830	MT
03/02	Rothschild & Co Redburn Adjusts Price Target on IDEXX Laboratories to $655 From $700	MT
09/12	Barclays Initiates IDEXX Laboratories With Overweight Rating, $850 Price Target	MT
10/11	Piper Sandler Adjusts Price Target on IDEXX Laboratories to $775 From $700	MT
04/11	UBS Adjusts Price Target on IDEXX Laboratories to $750 From $710, Maintains Neutral Rating	MT

More recommendations

Veterinary Medical Equipment & Supplies

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	IDEXX LABORATORIES, INC.					+34.31%
	ABBOTT LABORATORIES					+21.69%
	MEDTRONIC PLC					+21.49%
	STRYKER CORPORATION					+33.56%
	ESSILORLUXOTTICA					+59.76%
	CENCORA, INC.					+22.98%
	BECTON, DICKINSON AND COMPANY					+9.31%
	HOYA CORPORATION					+28.07%
	DEXCOM, INC.					+9.49%
	ALCON INC.					+41.14%
	Average					+28.18%
	Weighted average by Cap.					+28.10%